Evidence map›Paper›PMID 36855233›Full record

Trial reportClinical trials (London, England)2023

The Support, Educate, Empower personalized glaucoma coaching trial design.

Paula Anne Newman-Casey, Ken Resnicow, Suzanne Winter, Leslie M Niziol, Deborah Darnley-Fisch, Nauman Imami, Phalatha McHaney-Conner, David C Musch, Jamie Mitchell, Michele Heisler

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical trials (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Research Progress of Diabetes-related Glaucoma: Mechanisms, Impacts and Management Strategies.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Paula Anne Newman-CaseyDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-0847-1929
Ken ResnicowInstitute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA.
Suzanne WinterDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA.
Leslie M NiziolDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA.
Deborah Darnley-FischDepartment of Ophthalmology, Henry Ford Health System, Detroit, MI, USA.
Nauman ImamiDepartment of Ophthalmology, Henry Ford Health System, Detroit, MI, USA.
Phalatha McHaney-ConnerDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA.
David C MuschDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-4164-3841
Jamie MitchellSchool of Social Work, University of Michigan, Ann Arbor, MI, USA.
Michele HeislerInstitute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA.
University of Michigan · USHenry Ford Health System · US

Funding

Research BaseP30DK092926 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARY ELLEN MICHELE HEISLER, ADESUWA B OLOMU · 2011 to 2026
$10.0M
Support, Educate, Empower: The SEE Personalized Glaucoma Coaching Trial: Diversity SupplementR01EY031337 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NEWMAN-CASEY, PAULA ANNE · 2020 to 2024
$3.9M
NEI NIH HHS R01 EY031337NIDDK NIH HHS P30 DK092926
6 · The paper itself

Abstract

backgroundGlaucoma is a chronic disease that affects 3 million Americans. Glaucoma is most often asymptomatic until very late in its course when treatment is more difficult and extensive peripheral vision loss has already occurred. Taking daily medications can mitigate this vision loss, but at least half of people with glaucoma do not take their prescribed medications regularly. The purpose of this study is to improve glaucoma medication adherence among those with medically treated glaucoma and poor self-reported adherence using the Support, Educate, Empower personalized coaching program. METHODS/

designThis study is a two-site randomized controlled trial enrolling 230 participants with poor self-reported glaucoma medication adherence. The trial has two arms, an intervention arm and a control arm. Participants in the intervention arm receive personalized glaucoma education and motivational interviewing-based coaching over 6 months from a trained non-physician interventionist for three in-person sessions with between visit phone calls for check-ins where current adherence level is reported to participants. Participants also can elect to have visual, audio, text or automated phone call medication dose reminders. Participants in the control arm continue usual care with their physician and receive non-personalized glaucoma educational materials via mail in parallel to the three in-person coaching sessions to control for glaucoma knowledge content. All participants receive a medication adherence monitor. The primary outcome is the proportion of prescribed doses taken on schedule during the 6-month period. The secondary outcome is glaucoma related distress. The exploratory outcome is intraocular pressure. DISCUSSION: The personalized education and motivational-interviewing-based intervention that we are testing is comprehensive in that it addresses the wide range of barriers to adherence that people with glaucoma encounter. Leveraging a custom-built web-based application to generate the personalized content and the motivational-interviewing-based prompts to guide the coaching sessions will make this program both replicable and scalable and can be integrated into clinical care utilizing trained non-physician providers. Although this type of self-management support is not currently reimbursed for glaucoma as it is for diabetes, this trial could help shape future policy change should the intervention be found effective.

Indexed as

GlaucomaMentoringMotivational InterviewingTelecommunicationsHumansMedication AdherenceTelephoneGlaucomahealth coachingmedication adherencemotivational interviewingmulti-pronged interventionpersonalized educationrandomized controlled trialself-management supporttailored education

Identifiers

PMID36855233
PMCPMC10023277
OpenAlexW4322720255

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.